ABCODIA - Key Persons
Andrew is lead healthcare partner at Albion Ventures. Following biomedical research, he qualified as a surgeon, specializing in neurosurgery. He then joined the Boston Consulting Group (BCG) where he specialized in healthcare strategy, gaining experience with many large, global clients across the full spectrum of healthcare including biotechnology, pharmaceuticals, service and care providers, software and telecommunications. He oversees Albion Ventures' broad range of healthcare investing, from care provision to life science services, imaging and diagnostics.
Chris has over 25 years' experience in finance and has held senior positions at a variety of organization types, ranging from business start-ups to a FTSE 250 company. He joined Abcodia as CFO in October 2015. Before joining the company Chris was CFO at Zinwave Ltd, steering the company to its sale in 2014. He was the Finance Director at Enecsys Ltd. and played a fundamental role in numerous fund raising activities, (including Series B for $41m) to support the global growth of the organization.
Job Titles:
- Global Head, Information Technology
David has 25 years of experience leading Information Technology in life science companies with products including Stem Cell Banking, Human Genomics, and both software and hardware based Medical Devices. He has worked in early-stage commercial organizations, those making the transition from clinical to commercial strategies through IPO and acquisition, as well as PerkinElmer, a Fortune 1000 global healthcare company.
Dr. Andy Richards CBE is a well-established entrepreneur and builder of biotechnology, healthcare and diagnostic ventures. He brings a strong business focus and an in-depth knowledge of the industry and company scale up. In addition to Abcodia he is also currently Chairman of Congenica, Closed Loop Medicine and Arecor and a Director of Owlstone Medical and Ieso Digital Health. He is Chairman of the Babraham Research Campus and a director of Cancer Research Technology Ltd (the commercial board of Cancer Research UK). His early career spanned positions with ICI (now AstraZeneca) and PA Technology, and he was a founder and executive director of Chiroscience. Andy is a graduate of Cambridge University with a PhD in Chemistry and a track record as a founder, active investor in and director of more than 25 innovative healthcare and life-science companies, including Vectura plc and Arakis Ltd. Andy is also a founder member of the Cambridge Angels.
Job Titles:
- Non - Executive Director
- Member of the Investment Committee at Scottish Equity Partners
Jan is a Partner and member of the investment committee at Scottish Equity Partners (SEP), where she leads investments in high growth technology companies and oversees investments across the healthcare sector. A venture capital investor for the past 15 years, Jan joined SEP in 2004 from Dresdner Kleinwort Capital. Prior to moving into the investment field, she held operational and commercial roles in the pharmaceutical industry for, Merck, Novartis and Quintiles.
Job Titles:
- Founding CEO and Chief Scientific Officer
Julie has over 30 years of experience in Life Sciences, working in both public and private companies. She spent 15 years in pharmaceutical R&D, latterly with GlaxoSmithKline as Head of Neuroscience (1996-2001). Since then she has assumed several roles in small venture-backed companies active in software, medical device development and drug development, where she has lead scientific, regulatory and commercial strategy. In 2013, she won the WISE (Women in Science and Engineering) Award for Enterprise and Innovation.
Kate has over 25 years of life science experience working in both the public and private healthcare sectors. For the last 8 years she has worked specifically in investment; leading investments and serving on the boards of early stage companies in the life sciences and med tech sectors. Kate has held a diverse number of roles from initiating and growing start up diagnostics companies to leading Business Development in Europe for a multinational business. Much of Kate's time has been spent driving commercial activities and developing commercial strategies in order to grow businesses.
Dick has played a principal role in starting and building a number of medical diagnostic companies including that of founder, chairman, chief executive officer, and chief financial officer of DIANON Systems Inc.. He also served as chairman and chief financial officer of Lifecodes Corporation, a pioneer in DNA testing technology; chief financial officer and director of Matritech Inc., a company specializing in proteomic diagnostic products for the early detection of a variety of cancers. He is currently a Director of Oxford Immunotec a global diagnostics company providing advanced, innovative tests in the field of immunology.
Job Titles:
- Non - Executive Director
- Cambridge Innovation Capital As the Investment Director for Life Sciences
Robert joined Cambridge Innovation Capital as the Investment Director for Life Sciences in January 2014 after 20 years' experience in the pharma/biotech industry working both at large pharma (Sanofi, Roche), the MHRA and in VC backed companies (Arakis, KalVista) including founding the malaria therapeutics company Treague and as founding CEO of Avilex Pharma. Robert qualified in medicine at University College London; he is a member of the Royal College of Obstetricians and Gynecologists and the Faculty of Pharmaceutical Medicine. He has an MBA from London Business School and an MPhil in Biostatistics from the University of Cambridge.